Catscratch Disease Workup
- Author: Stephen J Nervi, MD; Chief Editor: Michael Stuart Bronze, MD more...
Consider all causes of subacute and chronic lymphadenopathy. However, infection with cytomegalovirus, human immunodeficiency virus type 1, or Epstein-Barr virus usually is associated with lymphadenitis at more than one site. In patients with persistent skin papules and regional lymphadenopathy, consider leishmaniasis, Nocardiosis, and fungal infections.
Because the clinical manifestations of infection with Bartonella henselae are different in patients who are immunocompromised, an entirely different differential diagnosis is appropriate. Bartonella infection leads to vasculoproliferative lesions, namely bacillary angiomatosis (B henselae, Bartonella quintana) and peliosis (B henselae only). The differential diagnosis includes malignant neoplasms (eg, Kaposi sarcoma, angiosarcoma) and benign reactive conditions (eg, pyogenic granuloma, angiolymphoid hyperplasia with eosinophilia).
Indirect fluorescence assay (IFA) testing and Enzyme-linked immunoassay (ELISA) are used to detect serum antibody to B henselae. An antibody titer that exceeds 1:64 suggests recent Bartonella infection. Paired acute and convalescent sera (drawn 6 wk apart) showing a 4-fold or greater increase is confirmatory. With IFA and ELISA tests, some cross-reactivity may occur between Bartonella species (especially B henselae and B quintana) and other bacteria such as Chlamydia psittaci.
IFA testing for Bartonella is quite variable, as many different tests are available; test sensitivity may be as low as 53% but is up to 100% in some series, with a specificity of 98%. About 84% of patients have positive titers within 1-2 weeks of clinical CSD, and 16% develop positive titers 4-8 weeks later.
Accuracy of IFA can be improved by concurrent use of both immunoglobulin G (IgG) and immunoglobulin M (IgM) testing. Specificity of IgM and IgG testing ranges from 88-98% and 50-62%, respectively. Most populations have low (2-6%) background seropositivity rates, limiting false-positive test results. The IFA shows cross-reactivity between Bartonella species, Epstein-Barr virus, cytomegalovirus, Toxoplasma gondii, and Streptococcus pyogenes.
ELISA testing for IgM has a sensitivity of 95% and a specificity of 77%. ELISA for IgG has a sensitivity of only 18%. Genotypic and phenotypic differences between B henselae strains are widely encountered and lead to antigenic variation and difficulty in interpreting the results of serologic tests.
A standard pattern of anti-B henselae IgG and IgM production does not seem to exist. Some patients with CSD have high levels of both IgG and IgM, some have high levels of only IgM, and others have low levels of both. The timing of IgG and IgM response is variable, and cross-reactivity between different Bartonella species may occur. In one study, 25% of patients remained IgG seropositive for longer than 1 year. Antibody kinetics do not reliably predict severity or duration of disease.
The prevalence of seropositivity in cats living in the same house as a human with CSD is 81%, versus 14-44% in unselected households.
Lymph node biopsy generally is not indicated in typical cases of CSD, given the associated morbidity and expense. Node aspiration in patients suspected of having CSD traditionally has been discouraged for fear of fistula formation. Consider performing a biopsy of an affected lymph node or skin in cases of possible malignancy or in an unclear presentation in an immunocompromised host. Ultrasonography may be performed to determine if a lymph node is fluctuant and amenable to needle aspiration.
PCR of a biopsy specimen is the most sensitive test and is able to differentiate between different Bartonella species, as well as subspecies and strains. However, this test is not readily available. A presumptive diagnosis of infection with CSD bacilli can be made with Warthin-Starry and Brown-Hopps gram-stained tissues. Immunostaining with BhmAB has been reported to be a better alternative than Warthin-Starry stain in demonstrating the organism.
The sensitivity of PCR with samples of lymph node tissue or aspirates is 30-60% for CSD. If histologic and serologic tests are coupled with PCR analysis, the sensitivity increases to 87%. A 2-step approach (initial testing by PCR/citrate synthase (CS) assay followed by PCR/rRNA assay for PCR/CS-negative specimens) has been suggested for patients in whom CSD is strongly suspected. PCR assays are available in some research and commercial laboratories.
Histopathological findings on biopsy depend on when in the course of the disease the biopsy is performed. Early findings include lymphoid and reticular cell hyperplasia and arteriolar proliferation. Later, granulomas with central necrosis often appear along with multinucleated giant cells. Microabscesses appear later.
Histopathological features of lymph nodes are consistent but not pathognomonic for CSD. Features include granuloma formation, stellate abscesses, and lymphocytic infiltrates. Brown-Hopp tissue Gram stain and Warthin-Starry silver staining can show clumps of small, curved, gram-negative bacilli (shown in the image below). These are usually found in the walls of blood vessels and in the microabscesses and macrophages that line the sinuses.
Culturing Bartonella species is difficult, as the ideal medium has not been established. Blood agar is often used, and incubation for up to 6 weeks is frequently necessary. Results are often negative.
Skin biopsy of the inoculation papule may be diagnostic. In patients with hepatosplenic CSD, liver and spleen biopsies may also show granulomas and abscesses.
The CSD skin test is no longer recommended. The test is less sensitive and specific than serologic testing, poorly standardized, and not approved by the US Food and Drug Administration (FDA). In addition, the test considered by some to be unsafe, as it uses a preparation derived from pus aspirated from suppurative lymph nodes of patients with CSD, and there is concern over the potential transmission of hepatitis viruses, HIV, and prions.
In patients with disseminated CSD and persistent high fever, abdominal pain, and severe systemic symptoms, abdominal CT scanning may be helpful. Multiple lesions of the liver and spleen are the major manifestations seen on such scans.
These lesions are usually round or oval, ranging from 3-30 mm, and hypodense on noncontrast CT scans. Injection of contrast material may yield hypodense, isodense, or marginally enhanced lesions when compared with normal parenchyma. Hepatosplenic lesions have been observed to spontaneously resolve or calcify over weeks to months.
The primary inoculation lesion site consists of variously shaped (round, triangular, stellate) areas of necrosis or necrobiosis surrounded by an inner zone of palisading epithelioid histiocytes with a few multinucleated giant cells and an outer zone of lymphocytes. Organisms (visualized with the Warthin-Starry stain or the Brown-Hopp modification of the Gram stain) appear in the necrotic areas singly, in chains, or in clusters.
Huang et al reported that with Warthin-Starry stain, the organisms were located outside the cells and were mainly in the necrotic debris, especially near the nodal capsule, while BhmAB immunostain showed the same localization but organisms were seen as dotlike granular, as well as a few linear, positive signals.
Histopathologic findings of the lymph nodes depend on the stage of infection. Lymphoid hyperplasia with arteriolar proliferation, reticulum cell hyperplasia, and widening of arteriolar walls are seen early in the disease. Progression of the disease is manifested by granulomas. The centers of these granulomas are acellular and necrotic with surrounding histiocytes and lymphocytes. Microabscesses may develop as the granulomas and areas of necrosis coalesce.
Lymphogranuloma inguinale, atypical mycobacteriosis, yersiniosis, tularemia, brucellosis, and chronic granulomatous disease of childhood may have histologic features similar to those of catscratch disease and should be considered in the differential diagnosis.
Histopathological examination of lymph nodes requires an invasive procedure; standard pathologic stains and Warthin Starry silver stain are nonspecific, and the staining procedure with the latter stain is technically difficult. The specificity of staining is improved with the use of immunohistochemical assay.
Warthin-Starry staining of involved lymph nodes may reveal chains, clumps, or clusters of pleomorphic B henselae bacilli. Organisms line the vascular sinuses. When necrosis is present, organisms may be seen within histiocytes as well as extracellularly in the necrotic areas and in the lumina of thrombosed blood vessels. Organisms are fewer in number in necrotic areas extensively infiltrated with neutrophils.
In many lymph nodes negative by culture, Rolain et al observed bacteria by direct immunofluorescence, which suggests that bacteria in lymph nodes are not viable.
In patients with hepatic involvement, hepatic parenchyma may be replaced by zones of organizing granulation tissue containing focal areas of granulomatous inflammation with stellate areas of central necrosis. The necrotic areas are infiltrated with neutrophils and are surrounded by palisading fibroblasts.
Bergman AM, Groothedde J-W, Schellekens JFP et al. Etiology of catscratch disease: a comparison of polymerase chain reaction detection of Bartonella and Afipia felis DNA with serology and skin tests. J Infect Dis. 1995. 171:916-923.
Carithers HA. Cat-scratch disease. An overview based on a study of 1,200 patients. Am J Dis Child. 1985 Nov. 139(11):1124-33. [Medline].
Moriarty RA, Margileth AM. Cat scratch disease. Infect Dis Clin North Am. 1987 Sep. 1(3):575-90. [Medline].
Abbasi S, Chesney PJ. Pulmonary manifestations of cat-scratch disease; a case report and review of the literature. Pediatr Infect Dis J. 1995 Jun. 14(6):547-8. [Medline].
Chrousos GA, Drack AV, Young M, Kattah J, Sirdofsky M. Neuroretinitis in cat scratch disease. J Clin Neuroophthalmol. 1990 Jun. 10(2):92-4. [Medline].
de Kort JG, Robben SG, Schrander JJ, van Rhijn LW. Multifocal osteomyelitis in a child: a rare manifestation of cat scratch disease: A case report and systematic review of the literature. J Pediatr Orthop B. Jul 2006. 15(4):285-8.
Giladi M,Champion I, Haake DA et al. Use of the blue hallo assay in the identification of genes encoding exported proteins with cleavable signal peptides:cloning of Borrelia burgdorferi plasmid gene with a signal peptide. J Bacteriol. 1993. 175:4129-4136.
Marra CM. Neurologic complications of Bartonella henselae infection. Curr Opin Neurol. 1995 Jun. 8(3):164-9. [Medline].
Walvogel K, Regnery RL, Anderson BE et al. Disseminated catscratch disease: detection of R.henselae in affected tissue. Eur. J. Pediatr. 1994. 153:23-27.
Rolain JM, Lepidi H, Zanaret M et al. Lymph node biopsy specimens and diagnosis of catscratch disease: discussion. Emerg Infect Dis. Sep 2006. 12(9):1338 -44.
Carithers HA. Cat-scratch disease; notes on its history. Am J Dis Child. 1970 Mar. 119(3):200-3. [Medline].
Margileth AM. The diagnostic challenge of cat scratch disease. Infect Med. 1987. 57-75.
Parinaud H. Conjonctivite infectieuse transmise par les animaux. Ann Oculistique. 1889. 101:252-253.
Debre R, Lamy M, Jammet ML. La maladie des griffes de chat. Semin Hop Paris. 1950. 26:1895-901.
GREER WE, KEEFER CS. Cat-scratch fever; a disease entity. N Engl J Med. 1951 Apr 12. 244(15):545-8. [Medline].
Wear DJ, Margileth AM, Hadfield TL, Fischer GW, Schlagel CJ, King FM. Cat scratch disease: a bacterial infection. Science. 1983 Sep 30. 221(4618):1403-5. [Medline].
Margileth AW, Wear DJ, Hadfield TL, Schlagel CJ, Spigel GT, Muhlbauer JE. Cat-scratch disease. Bacteria in skin at the primary inoculation site. JAMA. 1984 Aug 17. 252(7):928-31. [Medline].
English CK, Wear DJ, Margileth AM, Lissner CR, Walsh GP. Cat-scratch disease. Isolation and culture of the bacterial agent. JAMA. 1988 Mar 4. 259(9):1347-52. [Medline].
Alkan S, Morgan MB, Sandin RL, Moscinski LC, Ross CW. Dual role for Afipia felis and Rochalimaea henselae in cat-scratch disease. Lancet. 1995 Feb 11. 345(8946):385. [Medline].
Dolan MJ, Wong MT, Regnery RL, Jorgensen JH, Garcia M, Peters J, et al. Syndrome of Rochalimaea henselae adenitis suggesting cat scratch disease. Ann Intern Med. 1993 Mar 1. 118(5):331-6. [Medline].
Zangwill KM, Hamilton DH, Perkins BA, Regnery RL, Plikaytis BD, Hadler JL, et al. Cat scratch disease in Connecticut. Epidemiology, risk factors, and evaluation of a new diagnostic test. N Engl J Med. 1993 Jul 1. 329(1):8-13. [Medline].
Rolain JM, Chanet V, Laurichesse H, Lepidi H, Beytout J, Raoult D. Cat scratch disease with lymphadenitis, vertebral osteomyelitis, and spleen abscesses. Ann N Y Acad Sci. 2003 Jun. 990:397-403. [Medline].
Da Silva K, Chussid S. Cat scratch disease: clinical considerations for the pediatric dentist. Pediatr Dent. 2009 Jan-Feb. 31(1):58-62. [Medline].
Chen TC, Lin WR, Lu PL, Lin CY, Chen YH. Cat scratch disease from a domestic dog. J Formos Med Assoc. 2007 Feb. 106(2 Suppl):S65-68. [Medline].
Chomel BB, Kasten RW. Bartonellosis, an increasingly recognized zoonosis. J Appl Microbiol. 2010 Sep. 109(3):743-50. [Medline].
Lin JW, Chen CM, Chang CC. Unknown fever and back pain caused by Bartonella henselae in a veterinarian after a needle puncture: a case report and literature review. Vector Borne Zoonotic Dis. 2011 May. 11(5):589-91. [Medline].
Reynolds MG, Holman RC, Curns AT, O'Reilly M, McQuiston JH, Steiner CA. Epidemiology of cat-scratch disease hospitalizations among children in the United States. Pediatr Infect Dis J. 2005 Aug. 24(8):700-4. [Medline].
Sanguinetti-Morelli D, Angelakis E, Richet H, Davoust B, Rolain JM, Raoult D. Seasonality of cat-scratch disease, France, 1999-2009. Emerg Infect Dis. 2011 Apr. 17(4):705-7. [Medline].
Ridder GJ, Boedeker CC, Technau-Ihling K, Grunow R, Sander A. Role of cat-scratch disease in lymphadenopathy in the head and neck. Clin Infect Dis. 2002 Sep 15. 35(6):643-9. [Medline].
Fouch B, Coventry S. A case of fatal disseminated Bartonella henselae infection (cat-scratch disease) with encephalitis. Arch Pathol Lab Med. 2007 Oct. 131(10):1591-4. [Medline].
Gerber JE, Johnson JE, Scott MA, Madhusudhan KT. Fatal meningitis and encephalitis due to Bartonella henselae bacteria. J Forensic Sci. 2002 May. 47(3):640-4. [Medline].
Mosbacher ME, Klotz S, Klotz J, Pinnas JL. Bartonella henselae and the potential for arthropod vector-borne transmission. Vector Borne Zoonotic Dis. 2011 May. 11(5):471-7. [Medline].
Malatack JJ, Jaffe R. Granulomatous hepatitis in three children due to cat-scratch disease without peripheral adenopathy. An unrecognized cause of fever of unknown origin. Am J Dis Child. 1993 Sep. 147(9):949-53. [Medline].
Cheung VW, Moxham JP. Cat scratch disease presenting as acute mastoiditis. Laryngoscope. 2010. 120 Suppl 4:S222. [Medline].
Florin TA, Zaoutis TE, Zaoutis LB. Beyond cat scratch disease: widening spectrum of Bartonella henselae infection. Pediatrics. 2008 May. 121(5):e1413-25. [Medline].
Carithers HA, Margileth AM. Cat-scratch disease. Acute encephalopathy and other neurologic manifestations. Am J Dis Child. 1991 Jan. 145(1):98-101. [Medline].
Centers for Disease Control and Prevention. Encephalitis associated with cat scratch disease--Broward and Palm Beach Counties, Florida, 1994. MMWR Morb Mortal Wkly Rep. 1994 Dec 16. 43(49):909, 915-6. [Medline].
Pampe D, Holt RM. Cat scratch disease with reversible encephalopathy. Tex Med. 1984 Feb. 80(2):38-9. [Medline].
Pollen RH. Cat-scratch encephalitis. Neurology. 1968 Oct. 18(10):1031-3. [Medline].
Cherinet Y, Tomlinson R. Cat scratch disease presenting as acute encephalopathy. Emerg Med J. 2008 Oct. 25(10):703-4. [Medline].
Pickerill RG, Milder JE. Transverse myelitis associated with cat-scratch disease in an adult. JAMA. 1981 Dec 18. 246(24):2840-1. [Medline].
François J, Verriest G, De Laey JJ. Leber's idiopathic stellate retinopathy. Am J Ophthalmol. 1969 Aug. 68(2):340-5. [Medline].
Raoult D, Fournier PE, Drancourt M, Marrie TJ, Etienne J, Cosserat J, et al. Diagnosis of 22 new cases of Bartonella endocarditis. Ann Intern Med. 1996 Oct 15. 125(8):646-52. [Medline].
Hajjaji N, Hocqueloux L, Kerdraon R, Bret L. Bone infection in cat-scratch disease: a review of the literature. J Infect. 2007 May. 54(5):417-21. [Medline].
ten Hove CH, Gubler FM, Kiezebrink-Lindenhovius HH. Back pain in a child caused by cat scratch disease. Pediatr Infect Dis J. 2009 Mar. 28(3):258. [Medline].
Abarca K, Winter M, Marsac D, Palma C, Contreras AM, Ferrés M. [Accuracy and diagnostic utility of IgM in Bartonella henselae infections]. Rev Chilena Infectol. 2013 Apr. 30(2):125-8. [Medline].
Vermeulen MJ, Verbakel H, Notermans DW, Reimerink JH, Peeters MF. Evaluation of sensitivity, specificity and cross-reactivity in Bartonella henselae serology. J Med Microbiol. Mar 2010;(Epub ahead of print). 59:743-5. [Medline].
Huang J, Dai L, Lei S, et al. [Application of Warthin-Starry stain, immunohistochemistry and transmission electron microscopy in diagnosis of cat scratch disease]. Zhonghua Bing Li Xue Za Zhi. 2010 Apr. 39(4):225-9. [Medline].
Wang CW, Chang WC, Chao TK, Liu CC, Huang GS. Computed tomography and magnetic resonance imaging of cat-scratch disease: a report of two cases. Clin Imaging. 2009 Jul-Aug. 33(4):318-21. [Medline].
Min KW, Reed JA, Welch DF et al. Morphologically variable bacilli of catscratch disease identified by immunocytochemical labeling with antibodies to Rochalimaea Henselae. Am. J. Clin. Pathol. 1994. 101:607-610.
[Guideline] Stevens DL, Bisno AL, Chambers HF, Dellinger EP, Goldstein EJ, Gorbach SL, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of america. Clin Infect Dis. 2014 Jul 15. 59(2):e10-52. [Medline].
Dharnidharka VR, Richard GA, Neiberger RE, Fennell RS 3rd. Cat scratch disease and acute rejection after pediatric renal transplantation. Pediatr Transplant. 2002 Aug. 6(4):327-31. [Medline].
Bass JW, Freitas BC, Freitas AD, Sisler CL, Chan DS, Vincent JM, et al. Prospective randomized double blind placebo-controlled evaluation of azithromycin for treatment of cat-scratch disease. Pediatr Infect Dis J. 1998 Jun. 17(6):447-52. [Medline].
Margileth AM. Antibiotic therapy for cat-scratch disease: clinical study of therapeutic outcome in 268 patients and a review of the literature. Pediatr Infect Dis J. 1992 Jun. 11(6):474-8. [Medline].
Musso D, Drancourt M, Raoult D. Lack of bactericidal effect of antibiotics except aminoglycosides on Bartonella (Rochalimaea) henselae. J Antimicrob Chemother. 1995 Jul. 36(1):101-8. [Medline].
Ives TJ, Manzewitsch P, Regnery RL, Butts JD, Kebede M. In vitro susceptibilities of Bartonella henselae, B. quintana, B. elizabethae, Rickettsia rickettsii, R. conorii, R. akari, and R. prowazekii to macrolide antibiotics as determined by immunofluorescent-antibody analysis of infected Vero cell monolayers. Antimicrob Agents Chemother. 1997 Mar. 41(3):578-82. [Medline]. [Full Text].
Holley HP Jr. Successful treatment of cat-scratch disease with ciprofloxacin. JAMA. 1991 Mar 27. 265(12):1563-5. [Medline].
Bogue CW, Wise JD, Gray GF, Edwards KM. Antibiotic therapy for cat-scratch disease?. JAMA. 1989 Aug 11. 262(6):813-6. [Medline].
Koehler JE, LeBoit PE, Egbert BM, Berger TG. Cutaneous vascular lesions and disseminated cat-scratch disease in patients with the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. Ann Intern Med. 1988 Sep 15. 109(6):449-55. [Medline].
Koehler JE, Sanchez MA, Garrido CS, Whitfeld MJ, Chen FM, Berger TG, et al. Molecular epidemiology of bartonella infections in patients with bacillary angiomatosis-peliosis. N Engl J Med. 1997 Dec 25. 337(26):1876-83. [Medline].
|Sign or Symptom||Percentage, %||Average Duration, d|
|Fever >101°F (38.3°C)||32-60||6|
|Anorexia, weight loss, emesis||14||5|
n = 1174, %
n = 1200, %
|Inoculation lesion (skin, eye, mucous membrane)||58.6|
|Parinaud oculoglandular syndrome||6.3||4|
|Systemic disease, severe, chronic||2|
500 PO bid
|"Dramatic improvement" in a few days; defined as resolution of symptoms (ie, malaise and pain)||Holley|
5 mg/kg/d IV/IM
3 febrile children; 2 with hepatitis, 1 with painful regional lymphadenopathy
|Resolution of fever and systemic symptoms in 1-2 days||Bogue et al|
6-8 mg TMP/kg/d PO
|Uncontrolled retrospective study
60 patients with prolonged fever and systemic symptoms
|58% effective, 7-day course (see above)||Margileth|
|Rifampin 10-20 mg/kg/d PO/IV||Uncontrolled retrospective study
60 patients with prolonged fever and systemic symptoms
|87% effective, 7- to 14-day course (see above)||Margileth|
500 mg PO qd for 1 day, then 250 mg PO qd for 4 days
|Prospective placebo-controlled, double-blind study
|80% of lymph node volume (as measured by ultrasonography) resolved in 30 days in 7 of 15 patients on azithromycin vs 1 of 15 control patients||Bass et al|